RECURSION PHARMACEUTICALS, INC. (RXRX) Return on equity 2021–2025
RECURSION PHARMACEUTICALS, INC. (RXRX) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
-57.0%FY2025 · since FY2021: -34.3% → -57.0%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -57.0% | -12.2 pp |
| FY2024 | -44.8% | +26.0 pp |
| FY2023 | -70.8% | -21.5 pp |
| FY2022 | -49.3% | -14.9 pp |
| FY2021 | -34.3% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice